U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06839664) titled 'A Study of HS-20094 in Chinese Adults with Overweight or Obesity' on Feb. 18.
Brief Summary: The main purpose of this study is to assess the Efficacy and safety of HS-20094 in overweight and obese patients. The study will last up to approximately 52 weeks.
Study Start Date: Nov. 11, 2024
Study Type: INTERVENTIONAL
Condition:
Overweight
Obesity
Intervention:
DRUG: HS-20094 injection
Administered SC
DRUG: Placebo injection
Administered SC
Recruitment Status: RECRUITING
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....